Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
21 | DE file number | DAKZ | 602 13 842.6 |
96 | EP file number | EAKZ | 02 79 1654.3 |
86 | WO file number | WAKZ | PCT/EP02/12076 |
97 | EP publication number | EPN | 1441737 |
87 | WO publication number | WPN | 2003037347 |
54 | Designation/title | TI | STAUROSPORIN-DERIVATE ALS HEMMER DER FLT3-REZEPTOR-TYROSINKINASE-WIRKUNG |
51 | IPC main class | ICM (ICMV) | A61K 31/535 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 31/55 (2006.01), A61P 35/02 (2006.01), C07D 498/22 (2006.01), C07D 487/04 (2006.01), C07D 487/14 (2006.01), C07D 519/00 (2006.01) |
22 | DE application date | DAT | Oct 29, 2002 |
96 | EP application date | EAT | Oct 29, 2002 |
86 | WO application date | WAT | Oct 29, 2002 |
43 | Date of first publication | OT | May 8, 2003 |
| Date of publication of grant | PET | Aug 9, 2006 |
71/73 | Applicant/owner | INH | Novartis AG, 4056 Basel, CH; Dana-Farber Cancer Institute, Inc., Boston, Mass., US |
72 | Inventor | IN | GRIFFIN Douglas, James, Brookline, MA 02445, US; MANLEY William, Paul, CH-4144 Arlesheim, CH |
74 | Representative | VTR | Dr. Schön, Neymeyr & Partner mbB, 80336 München, DE |
10 | Published DE documents | DEPN | Original document:
DE000060213842T2 Searchable text:
DE000060213842T2 |
| Address for service | | Dr. Schön, Neymeyr & Partner Patentanwälte mbB, 80336 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 338185 P Dec 7, 2001
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 339031 P Oct 30, 2001
|
| Patent division in charge | | 44 |
21 | File number of protection certificate | ZAKZ | 12 2018 000 038.8 |
97 | EP language of publication | ELANG | EN - Englisch |
87 | WO language of publication | WLANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR |
81 | Designated WO countries | WDS | SI |
| Published EP/WO documents | EPWOPN | Original document:
EP000001441737 Searchable text:
EP000001441737 Original document:
EP000001441737B1 Searchable text:
EP000001441737B1 Original document:
WO002003037347 Searchable text:
WO002003037347 |
43 | Date of first publication | EVT | May 8, 2003 |
| Date of the first transfer into DPMAregister | EREGT | Sep 30, 2012 |
| Date of the (most recent) update in DPMAregister | REGT | Aug 3, 2023 (Show all update days)(Hide all update days)- Aug 3, 2023; Jun 24, 2023; Jun 22, 2023; Nov 1, 2022; Sep 29, 2021; Oct 16, 2020; Oct 23, 2019; Oct 23, 2018; Nov 7, 2017; Nov 9, 2016; Nov 8, 2016; Nov 11, 2015; Nov 5, 2015; Aug 25, 2015; Apr 15, 2015; Nov 13, 2014; Nov 5, 2014; Nov 8, 2013; Nov 2, 2013; Jan 26, 2013; Nov 6, 2012; Nov 2, 2012
- Historical data not available for this/these date(s)
- Sep 30, 2012
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 6)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Jul 13, 2006 |
71/73 | Applicant/owner | INH | Novartis AG, 4056 Basel, CH; Dana-Farber Cancer Institute, Inc., Boston, Mass., US |
71/73 | Previous applicant/owner | INHF | Novartis AG, 4056 Basel, CH, Novartis Pharma GmbH, Wien, AT, Dana-Farber Cancer Institute, Inc., Boston, Mass., US |